Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 12/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127749 | 0.86 | HCRTR1 (0.39) | HCRTR1HCRTR2CYP1A2CYP3A4THPO | |
| SCHEMBL982644 | 0.83 | HCRTR1 (0.44) | KDM4EHCRTR1HCRTR2 | |
| SCHEMBL982642 | 0.83 | HCRTR1 (0.44) | KDM4EHCRTR1HCRTR2 | |
| SCHEMBL2128177 | 0.81 | HCRTR1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL2126543 | 0.81 | HCRTR1 (0.52) | HCRTR1HCRTR2 | |
| SCHEMBL982926 | 0.79 | HCRTR1 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL1764517 | 0.78 | KDM4E (0.48) | KDM4EHCRTR1HCRTR2CYP1A2CYP3A4 | |
| SCHEMBL1764519 | 0.78 | KDM4E (0.48) | KDM4EHCRTR1HCRTR2CYP1A2CYP3A4 | |
| SCHEMBL2136587 | 0.75 | TSHR (0.44) | HCRTR1HCRTR2LMNA | |
| SCHEMBL2126228 | 0.73 | HCRTR1 (0.49) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236801-B2 | 2-aza-bicyclo[2.2.1]heptane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-07 | — | — | US | disclosed |
| EP-2247586-B1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | HCRTR2, HCRTR1, HCAR2 | KDM4E 933/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.